Cancer and ageing: Rival demons?

Nature Reviews Cancer

Volumn 3, Issue 5, 2003, Pages 339-349

  Campisi, Judith ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; APOPTOSIS; CANCER; CANCER CELL; CANCER CONTROL; CANCER INHIBITION; CANCER PREVENTION; EMBRYO DEVELOPMENT; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; CELL AGING; DNA REPAIR; GENETICS; GENOMICS; LONGEVITY; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

PROTEIN P53; RETINOBLASTOMA PROTEIN;

AGING; APOPTOSIS; CELL AGING; DNA REPAIR; GENOMICS; HUMANS; LONGEVITY; NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038049143     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1073     Document Type: Review

References (141)

1. Miller, R. A. Gerontology as oncology: research on aging as a key to the understanding of cancer. Cancer 68, 2496-2501 (1991).
2. DePinho, R. A. The age of cancer. Nature 408, 248-254 (2000).
3. Balducci, L. & Beghe, C. Cancer and age in the USA. Crit. Rev. Oncol. Hematol. 37, 137-145 (2001).
4. Kinzler, K. W. & Vogelstein, B. Cancer susceptibility genes: gatekeepers and caretakers. Nature 386, 761-763 (1997).
5. Barzilai, N. & Shuldiner, A. R. Searching for human longevity genes: the future history of gerontology in the post-genomic era. J. Gerontol. 56, 83-87 (2001).
6. Bookstein, R. & Lee, W. H. Molecular genetics of the retinoblastoma tumor suppressor gene. Crit. Rev. Oncol. 2, 211-227 (1991).
7. Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C. C. p53 mutation in human cancer. Science 253, 49-53 (1991).
8. Bishop, J. M. Cancer: the rise of the genetic paradigm. Genes Dev. 9, 1309-1315 (1995).
9. Wu, X. & Pandolfi, P. Mouse models for multistep tumorigenesis. Trends Cell Biol. 11, 2-9 (2001).
10. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
11. Compagni, A. & Christofori, G. Recent advances in research on multistage tumorigenesis. Br. J. Cancer. 83, 1-5 (2000).
12. Macleod, K. Tumor suppressor genes. Curr. Opin. Genet. Dev. 10, 81-93 (2000).
13. Weinberg, R. A. How cancer arises. Sci. Am. 275, 62-70 (1996).
14. Ghebranious, N. & Donehower, L. A. Mouse models in tumor suppression. Oncogene 17, 3385-3400 (1998).
15. Knudson, A. G. Chasing the cancer demon. Annu. Rev. Genet. 34, 1-19 (2000).
16. Hakem, R. & Mak, T. W. Animal models of tumor-suppressor genes. Annu. Rev. Genet. 35, 209-241 (2001).
17. Hasty, P., Campisi, J., Hoeijmakers, J., van Steeg, H. & Vijg, J. Aging and genome maintenance: lessons from the mouse? Science 299, 1355-1359 (2003).
18. Vijg, J. & Dolle, M. E. Large genome rearrangements as a primary cause of aging. Mech. Ageing Dev. 123, 907-915 (2002).
19. Rose, M. R. The Evolutionary Biology of Aging (Oxford Univ. Press, Oxford, 1991).
20. Kirkwood, T. B. & Austad, S. N. Why do we age? Nature 408, 233-238 (2000).
21. Umezu, K., Nakayama, K. & Nakayama, H. Escherichia coli RecQ protein is a DNA helicase. Proc. Natl Acad. Sci. USA 87, 5363-5367 (1990).
22. Gangloff, S., McDonald, J. P., Bendixen, C., Arthur, L. & Rothstein, R. The yeast type I topoisomerase Top3 interacts with Sgs1, a DNA helicase homolog: a potential eukaryotic reverse gyrase. Mol. Cell. Biol. 14, 8391-8398 (1994).
23. Stewart, E., Chapman, C. R., Al-Khodairy, F., Carr, A. M. & Enoch, T. Rqh1+, a fission yeast gene related to the Bloom's and Werner's syndrome genes, is required for reversible S phase arrest. EMBO J. 16, 2682-2692 (1997).
24. Frei, C. & Gasser, S. M. RecQ-like helicases: the DNA replication checkpoint connection. J. Cell Sci. 113, 2641-2646 (2000).
25. van Brabant, A. J., Stan, R. & Ellis, N. A. DNA helicases, genomic instability, and human genetic disease. Annu. Rev. Genom Hum. Genet. 1, 409-459 (2000).
26. Chakraverty, R. K. & Hickson, I. D. Defending genome integrity during DNA replication: a proposed role for RecQ family helicases. Bioessays 21, 286-294 (1999).
27. Goto, M. Hierarchical deterioration of body systems in Werner's syndrome: implications for normal ageing. Mech. Ageing Dev. 98, 239-254 (1997).
28. Martin, G. M., Oshima, J., Gray, M. D. & Poot, M. What genatricians should know about the Werner Syndrome. J. Am. Geriatr. Soc. 47, 1136-1144 (1999).
29. Ellis, N. A. & German, J. Molecular genetics of Bloom's syndrome. Hum. Mol. Genet. 5, 1457-1463 (1996).
30. Vennos, E. M. & James, W. D. Rothmund-Thomson syndrome. Dermatol. Clin. 13, 143-150 (1995).
31. Mohaghegh, P. & Hickson, I. D. DNA helicase deficiencies associated with cancer predisposition and premature ageing disorders Hum. Mol. Genet. 10, 741-746 (2001).
32. German, J. Bloom's syndrome. Dermatol. Clin. 13, 7-18 (1995).
33. Oshima, J. The Werner syndrome protein: an update Bioessays 22, 894-901 (2000).
34. Hickson, I. D. RecQ helicases: caretakers of the genome Nature Rev. Cancer 3, 169-178 (2003).
35. Chen, L. & Oshima, J. Werner Syndrome. J. Biomed. Biotechnol. 2, 46-54 (2002).
36. Fukuchi, K., Martin, G. M. & Monnat, R. J. Mutator phenotype of Werner syndrome is characterized by extensive deletions. Proc. Natl Acad. Sci. USA 66, 5893-5897 (1989).
37. Lebel, M. Increased frequency of DNA deletions in pink-eyed unstable mice carrying a mutation in the Werner syndrome gene homologue. Carcinogenesis 23, 213-216 (2002).
38. Oshima, J., Huang, S., Pae, C., Campisi, J. & Schiestl, R. H. Lack of WRN results in extensive deletion at nonhomologous joining ends. Cancer Res. 62, 547-551 (2002).
39. Prince, P.R., Emond, M. J. & Monnat, R. J. Loss of Werner syndrome protein function promotes aberrant mitotic recombination. Genes Dev. 15, 933-938 (2001).
40. Martin, G. M. Somatic mutagenesis and antimutagenesis in aging research. Mutat. Res. 350, 35-41 (1966).
41. Modrich, P. Mismatch repair, genetic stability, and cancer. Science 266, 1959-1960 (1994).
42. de Boer, J. & Hoeijmakers, J. Cancer from the outside, aging from the inside: mouse models to study the consequences of defective nucleotide excision repair. Biochimie 81, 127-137 (1999).
43. Lieber, M. R. Pathological and physiological double-strand breaks: roles in cancer, aging, and the immune system. Am. J. Pathol. 153, 1323-1332 (1998).
44. Modesti, M. & Kanaar, R. Homologous recombination: from model organisms to human disease. Genome Biol. 2, 1014 (2001).
45. Eisen, J. A. & Hanawalt, P. C. A phylogenomic study of DNA repair genes, proteins, and processes. Mutat. Res. 435, 171-213 (1999).
46. Burkle, A. Physiology and pathophysiology of poly(ADP-ribosyl)ation Bioessays 23, 795-806 (2001).
47. Friedberg, E. C. How nucleotide excision repair protects against cancer. Nature Rev. Cancer 1, 22-33 (2001).
48. Pierce, A. et al. Double-strand breaks and tumorigenesis. Trends Cell Biol. 11, 52-59 (2001).
49. Vogel, H., Lim, D. S., Karsenty, G., Finegold, M. & Hasty, P. Deletion of Ku86 causes early onset of senescence in mice. Proc. Natl Acad. Sci. USA 96, 10770-10775 (1999). Describes the premature ageing phenotypes of mice that are deficient in a protein required for repairing double-strand breaks in DNA.
50. Berneburg, M. & Lehmann, A. R. Xeroderma pigmentosum and related disorders: defects in DNA repair and transcription. Adv. Genet. 43, 71-102 (2001).
51. de Boer, J. et al. Premature aging in mice deficient in DNA repair and transcription. Science 296, 1276-1279 (2002). This paper describes the premature ageing phenotypes of mice deficient in a protein required for reparing damaged nucleotides in DNA.
52. Thompson, L. H. & Schild, D. Recombinational DNA repair and human disease. Mutat. Res. 509, 49-78 (2002).
53. Cao, L., Li, W., Kim, S., Brodie, S. G. & Deng, C. X. Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev. 17, 201-213 (2003).
54. Arends, M. J. & Wyllie, A. H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp. Pathol. 32, 223-254 (1991).
55. Ellis, R. E., Yuan, J. Y. & Horvitz, H. R. Mechanisms and functions of cell death. Annu. Rev. Cell Biol. 7, 663-698 (1991).
56. Vaux, D. L. & Korsmeyer, S. J. Cell death in development. Cell 96, 245-254 (1999).
57. Sinha Hakim, A. P. & Swerdloff, R. S. Hormonal and genetic control of germ cell apoptosis in the testis. Rev. Reprod. 4, 38-47 (1999).
58. Laun, P. et al. Aged mother cells of Saccharomyces cerevisiae show markers of oxidative stress and apoptosis. Mol. Microbiol. 39, 1166-1173 (2001).
59. Reed, J. C. Mechanisms of apoptosis in avoidance of cancer. Curr. Opin. Oncol. 11, 68-75 (1999).
60. Green, D. R. & Evan, G. I. A matter of life and death. Cancer Cell 1, 19-30 (2002).
61. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11, 27-31 (2001).
62. Kim, S. H., Kaminker P. & Campisi, J. Telomeres, aging and cancer: in search of a happy ending. Oncogene 21, 503-511 (2002).
63. Chiu, C. P. & Harley, C. B. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc. Soc. Exp. Biol. Med. 214, 99-106 (1997).
64. Campisi, J. Cancer, aging and cellular senescence. In Vivo 14, 183-188 (2000).
65. Serrano, M. & Blasco, M. A. Putting the stress on senescence. Curr. Opin. Cell Biol. 13, 748-753 (2001).
66. Campisi, J., Dimri, G. P. & Hara, E. in Handbook of the Biology of Aging (eds Schneider, E. & Rowe, J.) 121-149 (Academic Press, New York, 1996).
67. Linskens, M. H. K. et al. Cataloging altered gene expression in young and senescent cells using enhanced differential display. Nucl. Acids Res. 23, 3244-3251 (1995).
68. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis of replicative senescence. Curr. Biol. 9, 939-945 (1999). This paper uses microarrays to compare the senescent phenotype of replicatively senescent human fibroblasts with human fibroblasts that are induced to 'prematurely' senesce owing to nontelomeric events.
69. Campisi, J. From cells to organisms: can we learn about aging from cells in culture? Exp. Gerontol. 36, 607-618 (2001).
70. Margolis, J. & Spradling, A. Identification and behavior of epithelial stem cells in the Drosophila ovary. Development 121, 3797-3807 (1995).
71. Jazwinski, S. M. Longevity, Genes and Aging. Science 273, 54-59 (1996).
72. Sager, R. Senescence as a mode of tumor suppression. Environ. Health Persp. 93, 59-62 (1991).
73. Smith, J. R. & Pereira-Smith, O. M. Replicative senescence: implications for in vivo aging and tumor suppression. Science 273, 63-67 (1996).
74. Wright, W. E. & Shay, J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting. Curr. Opin. Genet. Dev. 11, 98-103 (2001).
75. Yeager, T. R. et al. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev. 12, 163-174 (1998).
76. Serrano, M. et al. Role of the INK4A locus in tumor suppression and cell mortality. Cell 85, 27-37 (1996).
77. Sharpless, N. E. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumongenesis. Nature 413, 86-91 (2001).
78. Harvey, M. et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8, 2457-2467 (1993).
79. Donehower, L. A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356, 215-221 (1992).
80. Hara, E. et al. Regulation of p16/CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16, 859-867 (1996).
81. McConnell, B. B., Starborg, M., Brookes, S. & Peters, G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr. Biol. 8, 351-354 (1998).
82. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
83. Alcorta, D. A. et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA 93, 13742-13747 (1996).
84. Dimri, G. P. Itahana, K., Acosta, M. & Campisi, J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14/ARF tumor suppressor. Mol. Cell. Biol. 20, 273-285 (2000).
85. Stein, G. H., Beeson, M. & Gordon, L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science 249, 666-669 (1991).
86. Futreal, P. A. & Barrett, J. C. Failure of senescent cells to phosphorylate the RB protein. Oncogene 6, 1109-1113 (1991).
87. Atadja, P., Wong, H., Garkavstev, I., Veillette, C. & Riabowol, K. Increased activity of p53 in senescing fibroblasts. Proc. Natl Acad. Sci. USA 92, 8348-8352 (1995).
88. DiLeonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 8, 2540-2551 (1994).
89. 2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G(1) arrest but not cell replication. Biochem. J. 332, 43-50 (1998).
90. Hara, E., Tsuri, H., Shinozaki, S. & Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of lifespan in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Comm. 179, 528-534 (1991).
91. Shay, J. W., Pereira-Smith, O. M. & Wright, W. E. A role for both Rb and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196, 33-39 (1991).
92. Gire, V. & Wynford-Thomas, D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol. Cell. Biol. 18, 1611-1621 (1998).
93. Lundberg, A. S., Hahn, W. C., Gupta, P. & Weinberg, R. A. Genes involved in senescence and immortalization. Curr. Opin. Cell Biol. 12, 705-709 (2000).
94. Bringold, F. & Serrano, M. Tumor suppressors and oncogenes in cellular senescence. Exp. Gerontol. 35, 317-329 (2000).
95. Itahana, K., Dimri, G. & Campisi, J. Regulation of cellular senescence by p53. Eur. J. Biochem. 268, 2784-2791 (2001).
96. Sharpless, N. E. & DePinho, R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22-30 (1999).
97. Dai, C. Y. & Enders, G. H. p16 INK4a can initiate an autonomous senescence program. Oncogene 19, 1613-1622 (2000).
98. Sugrue, M. M., Shin, D. Y., Lee, S. W. & Aaronson, S. A. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc. Natl Acad. Sci. USA 94, 9648-9653 (1997).
99. Xu, H. J. et al. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15, 2589-2596 (1997).
100. Amundson, S. A. Myers, T. G. & Fornace, A. J. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17, 3287-3299 (1998).
101. Prives, C. & Hall, P. A. The p53 pathway. J. Pathol. 187, 112-126 (1999).
102. Bargonetti, J. & Manfredi, J. J. Multiple roles of the tumor suppressor p53. Curr. Opin. Oncol. 14, 86-91 (2002).
103. Wahl, G. M. & Carr, A. M. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nature Cell Biol. 3, 277-286 (2001).
104. Lu, X. & Horvitz, H. R. Iin-35 and Iin-53, two genes that antagonize a C. elegans Ras pathway, encode proteins similar to Rb and its binding protein RbbAp48. Cell 95, 981-991 (1998).
105. Du, W., Vidal, M., Xie, J. E. & Dyson, N. RBF, a novel RB-related gene that regulates E2F activity and interacts with cyclin E in Drosophila. Genes Dev. 10, 1206-1218 (1996).
106. Derry, W. B., Putzke, A. P. & Rothman, J. H. Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance Science 294, 591-595 (2001).
107. Schumacher, B., Hoffman, K., Boulton, S. & Gartner, A. The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr. Biol. 11, 1722-1727 (2001).
108. Brodsky, M. H. et al. Drosophila p53 binds a damage response element at the reaper locus. Cell 101, 103-113 (2000).
109. Ollmann, M. et al. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell 101, 91-101 (2000).
110. Jin, S. et al. Identification and characterization of a p53 homologue in Drosophila melanogaster. Proc. Natl Acad. Sci. USA 97, 7301-7306 (2000). References 106-110 describe the conserved sequence and functions of invertebrate (C. elegans and D. melanogaster) p53.
111. Finch, C. R. Longevity, Senescence and the Genome (Univ Chicago Press, Chicago, 1991).
112. Williams, G. C. Pleiotropy, natural selection, and the evolution of senescence. Evolution 11, 398-411 (1957).
113. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456-1462 (1995).
114. Fadeel, B., Orrenius, S. & Zhivotovsky, B. Apoptosis in human disease: a new skin for an old ceremony? Biochem. Biophys. Res. Comm. 266, 699-717 (1999).
115. Martin, L. J. Neuronal cell death in nervous system development, disease, and injury. Int. J. Mol. Med. 7, 455-478 (2001).
116. Almeida-Porada, G., Porada, C. & Zanjani, E. D. Adult stem cell plasticity and methods of detection. Rev. Clin. Exp. Hematol 5, 26-41 (2001).
117. Weissman, I. L., Anderson, D. J. & Gage, F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 17, 387-403 (2001).
118. Weinstein, B. S. & Ciszek, D. The reserve capacity hypothesis: evolutionary origins and modern implications between tumor suppression and tissue repair. Exp. Gerontol. 37, 615-627 (2002).
119. Donehower, L. A Does p53 affect organismal aging? J. Cell Physiol. 192, 23-33 (2002).
120. Krtolica, A. & Campisi, J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int. J. Biochem. Cell Biol. 34, 1401-1414 (2002).
121. Dimri, G. P. et al. A novel biomarker identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
122. Choi, J. et al. Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology 56, 160-166 (2000).
123. Paradis, V. et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum. Pathol. 32, 327-332 (2001).
124. Vasile, E., Tomita, Y., Brown, L. F., Kocher, O. & Dvorak, H. F. Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis. FASEB J. 15, 458-466 (2001). References 121-124 describe some of the evidence that senescent cells exist, accumulate with age and contribute to age-related pathology in vivo.
125. Fusenig, N. E. & Boukamp, P. Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes. Mol. Carcinog. 23, 144-158 (1998).
126. Olumi, A. F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999). Shows that fibroblasts, if appropriately stimulated, can facilitate the neoplastic progression of epithelial cells.
127. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072-12077 (2001). Shows that senescent human fibroblasts can promote the neoplastic progression of preneoplastic epithelial cells.
128. Tyner, S. D et al. p53 mutant mice that display early aging-associated phenotypes. Nature 415, 45-53 (2002). Shows that increased p53 activity suppresses the development of cancer in mice, but also promotes the premature development of ageing phenotypes.
129. Garcia-Cao, I. et al. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225-6235 (2002).
130. Davenport, J. Tumor-free but not in the clear. Science. SAGE-KE, 2002.
131. Gray, J. W. & Collins, C. Genome changes and gene expression in human solid tumors Carcinog. 21, 443-452 (2000).
132. Jonason, A. S. et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc. Natl Acad. Sci. USA 93, 14025-14029 (1996). Shows that potentially oncogenic cells - in this case, harbouring TP53 mutations - are present in apparently normal young human tissue.
133. Aubele, M. et al. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Int. J. Cancer 85, 82-86 (2000).
134. Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D. & Smith, H. S. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274, 2057-2059 (1996). Shows that apparently normal human tissue harbours potentially oncogenic mutations.
135. Umayahara, K. et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosom. Cancer 33, 98-102 (2002).
136. Ilmensee, K. Reversion of malignancy and normalized differentiation of teratocarcinoma cells in chimeric mice. Basic Life Sci. 12, 3-25 (1978). Shows that potentially malignant cells can fail to express their neoplastic properties when placed in a normal tissue microenvironment.
137. Liotta, L. A. & Kohn, E. C. The microenvironment of the tumour-host interface. Nature 411, 375-379 (2001).
138. Park, C. C., Bissell, M. J. & Barcellos-Hoff, M. H. The influence of the microenvironment on the malignant phenotype. Molec. Med. Today 6, 324-329 (2000).
139. Yap, D. B., Hsieh, J. K., Chan, F. S. & Lu, X. Mdm2: a bridge over the two tumour suppressors, p53 and Rb. Oncogene 18, 7681-7689 (1999).
140. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999).
141. Dyson, N. The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262 (1998).